Have a feature idea you'd love to see implemented?
Let us know!
RGNX REGENXBIO Inc
Price (delayed)
$9.735
Market cap
$481.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.26
Enterprise value
$506.88M
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
Highlights
RGNX's EPS is up by 17% year-on-year and by 10% since the previous quarter
The net income is up by 12% YoY and by 7% from the previous quarter
RGNX's gross profit is down by 12% year-on-year but it is up by 2.5% since the previous quarter
The company's revenue fell by 8% YoY but it rose by 2.7% QoQ
The equity has contracted by 14% YoY and by 11% from the previous quarter
The gross margin has declined by 4.2% year-on-year
Key stats
What are the main financial stats of RGNX
Market
Valuations
Earnings
Shares outstanding
49.42M
Market cap
$481.13M
Enterprise value
$506.88M
Price to book (P/B)
1.38
Price to sales (P/S)
5.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.69
Revenue
$89.04M
EBIT
-$235.82M
EBITDA
-$218.88M
Free cash flow
-$194.72M
Per share
Balance sheet
Liquidity
EPS
-$5.26
Free cash flow per share
-$3.85
Book value per share
$7.07
Revenue per share
$1.76
TBVPS
$11.25
Total assets
$569.38M
Total liabilities
$221.11M
Debt
$85.54M
Equity
$348.27M
Working capital
$248.41M
Debt to equity
0.25
Current ratio
3.53
Quick ratio
3.21
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
-245.8%
Gross margin
56.8%
Net margin
-270.7%
Operating margin
-279.4%
Return on assets
-40.1%
Return on equity
-68.2%
Return on invested capital
-46.5%
Return on capital employed
-50.1%
Return on sales
-264.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGNX stock price
How has the REGENXBIO stock price performed over time
Intraday
1.51%
1 week
-9.44%
1 month
-16.58%
1 year
-37.48%
YTD
-45.77%
QTD
-7.2%
Financial performance
How have REGENXBIO's revenue and profit performed over time
Revenue
$89.04M
Gross profit
$50.56M
Operating income
-$248.76M
Net income
-$241.08M
Gross margin
56.8%
Net margin
-270.7%
The net income is up by 12% YoY and by 7% from the previous quarter
RGNX's gross profit is down by 12% year-on-year but it is up by 2.5% since the previous quarter
REGENXBIO's net margin has increased by 10% QoQ and by 4.2% YoY
RGNX's operating margin is up by 9% since the previous quarter
Growth
What is REGENXBIO's growth rate over time
Valuation
What is REGENXBIO stock price valuation
P/E
N/A
P/B
1.38
P/S
5.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.69
RGNX's EPS is up by 17% year-on-year and by 10% since the previous quarter
RGNX's P/B is 46% below its 5-year quarterly average of 2.5 and 35% below its last 4 quarters average of 2.1
The equity has contracted by 14% YoY and by 11% from the previous quarter
The price to sales (P/S) is 52% lower than the 5-year quarterly average of 11.3 and 35% lower than the last 4 quarters average of 8.4
The company's revenue fell by 8% YoY but it rose by 2.7% QoQ
Efficiency
How efficient is REGENXBIO business performance
The ROE is down by 21% YoY but it is up by 3.5% QoQ
The ROIC has contracted by 19% YoY but it has grown by 3.3% from the previous quarter
REGENXBIO's ROA has decreased by 15% YoY but it has increased by 2.9% from the previous quarter
RGNX's return on sales is up by 10% since the previous quarter
Dividends
What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGNX.
Financial health
How did REGENXBIO financials performed over time
RGNX's total assets is 158% greater than its total liabilities
RGNX's total liabilities is down by 20% year-on-year and by 7% since the previous quarter
RGNX's total assets is down by 17% year-on-year and by 10% since the previous quarter
REGENXBIO's debt is 75% lower than its equity
The equity has contracted by 14% YoY and by 11% from the previous quarter
RGNX's debt to equity is up by 14% since the previous quarter and by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.